Therapeutic Response Statement (Sensitivity)
This therapeutic response statement Supports the relationship that PD-L1 (TAP) >= 5% status confers therapeutic sensitivity to Capecitabine, Oxaliplatin, Tislelizumab in patients with Esophageal Squamous Cell Carcinoma.
The Republic of Ireland's Health Service Executive (HSE) has approved tislelizumab in combination with CAPOX (capecitabine and oxaliplatin) as a treatment option for the first-line treatment of adult patients with unresectable, locally advanced or metastatic esophageal squamous cell carcinoma (ESCC) whose tumors express programmed death-ligand (PD-L1) with a tumor area positivity (TAP) score >= 5%. The treatment regimen further states that, as the platinum and fluoropyrimidine based chemotherapy is not defined in the EMA licensed indication, other evidence-based platinum and fluoropyrimidine regimens may be used in combination with tislelizumab.
This statement is based on a regulatory approval from the Health Service Executive:
First-line treatment of adult patients with unresectable, locally advanced or metastatic oesophageal squamous cell carcinoma (OSCC) whose tumours express programmed death-ligand (PD-L1) with a tumour area positivity (TAP) score >= 5%.